|1.||Koide, Hikaru: 3 articles (01/2005 - 01/2002)|
|2.||Nakamura, Tsukasa: 3 articles (01/2005 - 01/2002)|
|3.||Koide, H: 3 articles (05/2001 - 07/2000)|
|4.||Ebihara, I: 3 articles (05/2001 - 07/2000)|
|5.||Shimada, N: 3 articles (05/2001 - 07/2000)|
|6.||Ushiyama, C: 3 articles (05/2001 - 07/2000)|
|7.||Nakamura, T: 3 articles (05/2001 - 07/2000)|
|8.||Passer, Brent J: 2 articles (12/2014 - 05/2010)|
|9.||Buolamwini, John K: 2 articles (12/2014 - 05/2010)|
|10.||Matsuda, Takaharu: 2 articles (01/2005 - 09/2002)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
11/01/1995 - "Clinical effects of an anti-platelet drug (dilazep dihydrochloride) in the microalbuminuric stage of diabetic nephropathy were investigated in a multi-center study. "
11/01/1995 - "Clinical effect of the anti-platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy--a multi-center study."
01/01/2002 - "Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats."
08/01/2000 - "Podocyte injury may occur in patients with early diabetic nephropathy, and dilazep dihydrochloride may be useful for preventing glomerular injury."
08/01/2000 - "Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy."
01/01/1983 - "Efficacy of Dilazep in patients with previous myocardial infarction participating in a cardiac rehabilitation programme."
05/01/1989 - "Effects of dilazep in evolving myocardial infarction in dogs: a biochemical study."
01/01/1983 - "The present investigation was undertaken to evaluate the effects of Dilazep, a new antiplatelet and coronary dilating drug, on the exercise tolerance of patients who had suffered previous myocardial infarction and were participating in a cardiac rehabilitation programme. "
01/01/1974 - "The effect of dilazep on blood flow and oxygen handling in the early stages of canine myocardial infarction. "
|3.||IGA Glomerulonephritis (IGA Nephropathy)
11/01/2000 - "These findings suggest that treatment with dilazep might improve the clinical and immunopathological findings in IgA nephropathy of ddY mice."
11/01/2000 - "We determined the clinical and immunopathological effects of dilazep hydrochloride (dilazep) on IgA nephropathy of ddY mice. "
11/01/2000 - "Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice."
04/01/1994 - "These findings suggest that an anti-proteinuric effect of Dilazep administration can be expected in patients with IgA nephropathy with relatively mild glomerulo-sclerotic lesions."
04/01/1994 - "To investigate renal biopsy findings arising in response to treatment with an anti-platelet drug in IgA nephropathy, 46 patients were treated with dilazep dihydrochloride (Dilazep), and a retrospective comparison was performed between the clinical effects and renal biopsy findings. "
05/19/1989 - "Whereas dilazep (i.p.) produced no apparent central nervous system (CNS) effects, by i.c.v. route, it caused CNS excitation including tonic-clonic seizures. "
07/13/1990 - "Moreover, dilazep, an effective blocker of adenosine uptake, when co-administered with KA, provides significant protection against seizures. "
05/19/1989 - "The data also suggest that dilazep (i.c.v.)-induced seizures are due to mechanism(s) other than adenosine uptake inhibition, Ca2+ entry blockade or direct adenosine receptor activation."
03/01/1993 - "Administration of exogenous adenosine afforded a dose-dependent protection (ED50 = 48.1 +/- 8.4 nmol) against bicuculline methiodide-induced seizures, and these anticonvulsant effects were significantly potentiated by treatment with an adenosine kinase inhibitor, 5'-amino-5'-deoxyadenosine; by the adenosine transport blockers, dilazep or nitrobenzylthioinosine 5'-monophosphate; and by an adenosine deaminase inhibitor, 2'-deoxycoformycin. "
07/01/1983 - "Twenty patients suffering from heart failure of ischemic or ischemic plus valvular etiologies, undergoing digitalis treatment for at least 3 weeks, were administered dilazep (300 mg/day). "
07/01/1983 - "Contemporaneous administration of digitalis and dilazep to subjects with heart failure of ischemic etiology."
04/01/1999 - "In addition, we found that further elevation of plasma adenosine levels due to either dipyridamole or dilazep reduces the severity of chronic heart failure. "
07/01/1998 - "In patients with chronic heart failure, either dipyridamole (300 mg/d n = 17) or dilazep (300 mg/d n = 5) were administered for 6 months. "
07/01/1998 - "Since we have reported that adenosine levels increase in patients with chronic heart failure, we tested whether further elevation of the adenosine levels due to dipyridamole or dilazep for 6 months modulates the pathophysiology of chronic heart failure. "
|4.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|1.||Sodium-Restricted Diet (Diet, Sodium Restricted)
|3.||Angioplasty (Angioplasty, Transluminal)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Tooth Extraction (Tooth Extractions)